[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352476-105":59,"doc-detail-352476-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-structure-pathogenesis-and-inhibition-of-the-p53-mdm2-pathway","The Structure, Pathogenesis, and Inhibition of the p53-MDM2 Pathway","","The review explains how dysregulation of the p53 tumor suppressor is a common driver of cancer and how MDM2, a negative regulator E3 ubiquitin ligase, disrupts p53 through direct binding and proteasomal degradation. It summarizes MDM2 structural elements, emphasizing the N-terminal hydrophobic pocket and C-terminal RING domain, and links MDM2 overexpression or amplification to tumorigenesis even when p53 is wild type. It also evaluates pathological effects and SNPs associated with elevated cancer risk, highlighting small-molecule non-covalent MDM2 inhibitors such as rhein-derived AQ-101.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-structure-pathogenesis-and-inhibition-of-the-p53-mdm2-pathway/352476/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-structure-pathogenesis-and-inhibition-of-the-p53-mdm2-pathway/352476.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does MDM2 regulate p53 under normal and cancer-promoting conditions?","Question",{"text":112,"@type":113},"MDM2 negatively regulates p53 by direct binding and promoting proteasomal degradation. When MDM2 is overexpressed or amplified, the pathway is disrupted and tumorigenesis can increase even with wild-type p53.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which structural features of MDM2 are emphasized in the review?",{"text":117,"@type":113},"The review highlights the N-terminal hydrophobic pocket and the C-terminal RING domain. These regions are presented as key to MDM2’s ability to impose negative feedback on p53.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic strategies are discussed for targeting the p53-MDM2 pathway?",{"text":121,"@type":113},"The review surveys approaches that target the p53-MDM2 axis and focuses on inhibiting the MDM2 RING domain. It especially discusses small-molecule non-covalent inhibitors, including rhein-derived anthraquinone analogs such as AQ-101.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352476,1790739873,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Review  \nThe Structure, Pathogenesis, and Inhibition of thep53-MDM2 Pathway  \nAmanda L. Brown 1, Xiaoying Lian 2 and Qian Wang 2, *  \nAcademic Editor: Gianluca Aguiari  \nReceived: 7 January 2026  \nRevised: 5 February 2026  \nAccepted: 5 February 2026  \nPublished: 7 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 School of Medicine, University of South Carolina, Columbia, SC 29209, USA; [amanda.brown@uscmed.sc.edu](amanda.brown@uscmed.sc.edu)  \n2 Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, USA; [xl27@email.sc.edu](xl27@email.sc.edu)  \n* [Correspondence: wang263@mailbox.sc.edu](Correspondence: wang263@mailbox.sc.edu)  \nSimple Summary  \nDysregulation of the p53 tumor suppressor protein has been shown to be a common mechanism underlying the pathogenesis of various types of cancers. A major protein involved in p53 disruption and degradation is the negative regulator MDM2 . Several compounds targeting the p53-MDM2 pathway have been developed as promising anti-cancer therapies. Most of these strategies have acted against the p53-MDM2 binding interaction; however, recent research has turned toward inhibiting the MDM2 RING domain. In this review, we outline the structural features of the MDM2 protein, summarize its role in cancer pathogenesis, and review current and promising therapeutic strategies for targeting thep53-MDM2 pathway.  \nAbstract  \nThe p53 tumor suppressor protein plays a central role in maintaining genomic stability by regulating cell cycle arrest, apoptosis, and DNA repair under cellular stress. Mouse double minute 2 (MDM2), an E3 ubiquitin ligase, negatively regulates p53 via direct binding and proteasomal degradation. Overexpression or amplification of MDM2 can disrupt this pathway and promote tumorigenesis, even in cancers with wild-type p53 . This review outlines the structural features of MDM2, particularly its N-terminal hydrophobic pocket and C-terminal RING domain, and their roles in p53 regulation. We further examine the pathological effects of MDM2 dysregulation and SNPs linked to increased cancer risk. Recent progress in small molecule MDM2 inhibitors is discussed, with a focus on non-covalent agents such as rhein-derived anthraquinone analogs, including AQ-101, which demonstrate promising anti-cancer activity with reduced toxicity. These findings support the continued development of non-covalent MDM2 inhibitors as a novel therapeutic approach for cancers involving both wild-type and mutant p53 .  \nKeywords: p53; MDM2 RING domain; MDM2 inhibition; targeted therapy; non-covalent inhibition; rhein-derived compounds  \n1. Introduction  \np53 is a tumor suppressor protein that is crucial in coordinating a cell’s response following DNA damage or cellular stress. The important nature of p53 for regulating cellular growth is highlighted by the fact that many cancers, of which uncontrolled cell growth is a hallmark, are associated with mutated or dysregulated p53 [1] . p53 acts as a transcription factor for various genes whose products are responsible for inhibiting cell  \nproliferation in response to DNA damage, either by halting the cell cycle, prompting cellular senescence, or initiating apoptosis [2] . If translocated out of the nucleus and to the mitochondria, p53 can also act as a transcription-independent catalyst for mitochondrial apoptosis [3] . Critical to p53’s function is its ability to induce expression of proteins that modify its own activity via positive or negative feedback. One such protein, mouse double minute 2 (MDM2), is vital to many of p53’s negative feedback loops by operating primarily as an E3 ubiquitin ligase to mark p53 for proteasomal degradation [1,4,5] . While other proteins have been found to play a role in p53 regulation, such as the E3 ligases Cop1 and Pirh-1, these a","cbCaiui5qEZS2qjT","https://ap.wps.com/l/cbCaiui5qEZS2qjT","pdf",2690258,15,"English","# Simple Summary\n# Abstract\n# Keywords\n# Introduction\n# General Structure and Function of the p53-MDM2 Complex","[{\"question\":\"How does MDM2 regulate p53 under normal and cancer-promoting conditions?\",\"answer\":\"MDM2 negatively regulates p53 by direct binding and promoting proteasomal degradation. When MDM2 is overexpressed or amplified, the pathway is disrupted and tumorigenesis can increase even with wild-type p53.\"},{\"question\":\"Which structural features of MDM2 are emphasized in the review?\",\"answer\":\"The review highlights the N-terminal hydrophobic pocket and the C-terminal RING domain. These regions are presented as key to MDM2’s ability to impose negative feedback on p53.\"},{\"question\":\"What therapeutic strategies are discussed for targeting the p53-MDM2 pathway?\",\"answer\":\"The review surveys approaches that target the p53-MDM2 axis and focuses on inhibiting the MDM2 RING domain. It especially discusses small-molecule non-covalent inhibitors, including rhein-derived anthraquinone analogs such as AQ-101.\"}]","The Structure, Pathogenesis, and Inhibition of the p53-MDM2 Pathway | PDF",1790099846,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d06ea2db8b52840a9a158f51631a1d78.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f49355fef3c0f1ef02edf541c599071.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4c23da631d9c5877f1bf73081b8d09c.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bcb3e1aa6a2296489d5f07b4beb9aee.webp",980,1385]